Reading the tape
NASDAQ: ONCO
Onconetix, Inc.
Healthcare · Biotechnology
Market Cap
$3.73M
52w High
$74.38
52w Low
$1.01
P/E
-0.25
Volume
12.80M
Outstanding Shares
3.43M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -95.58%Revenue (TTM): -67.7%FCF (TTM): 8.04%P/S: 0th pct
What changed
The stock fell 95.58% over the last year. Revenue declined 67.7% over the trailing twelve months. Operating margin moved from -2,237.96% to -2,190.03%. Free cash flow grew 8.04% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -2,190.03%. A decisive move in revenue — currently down 67.7% — would be the clearest signal to resolve the ambiguity.
Company profile
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide.
CEODavid Allan White
SectorHealthcare
IndustryBiotechnology
Employees12
IPO dateFeb 18, 2022
Valuation
Forward P/E—
EV/EBITDA-3.23
Enterprise value$20.43M
Stock splits
Mar 25, 2026↓ Reverse
Every 5 shares became 1
Jun 13, 2025↓ Reverse
Every 85 shares became 1
Sep 24, 2024↓ Reverse
Every 40 shares became 1
Profitability & growth
Revenue growth-57.36%
Gross margin77.62%▲85.70%vs FY2024
Operating margin-2,190.03%▲65.23%vs FY2024
ROE-89.01%▲85.42%vs FY2024
Analyst consensus
RatingBuy
Target price—
1
Buy
1
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 11, 2026
View
EPS
Actual vs estimate by quarter
Q3FY25
ActualEst.
-$4.05
—
Q4FY25
ActualEst.
-$6.25
—
Q1FY26
ActualEst.
$12.58
—
Q2FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q3FY25
ActualEst.
$106.49K
—
Q4FY25
ActualEst.
$303.65K
—
Q1FY26
ActualEst.
$303.6K
—
Q2FY26
Next Est.
—